{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:08:22Z","timestamp":1769724502631,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To determine the prevalence of Latent Tuberculosis in patients with hematological neoplasms at the Instituto Nacional de Cancerolog\u00eda in Mexico City using the Tuberculin skin test (TST).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective study included all patients with a recent diagnosis of hematological neoplasms who were admitted for treatment from 2017 to 2018 and who were screened for latent tuberculosis with the TST. The prevalence of latent tuberculosis in this group, tolerance and therapeutic adherence in treated patients are described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The files of 446 patients with hematological malignancy who had a TST were reviewed. The prevalence of latent tuberculosis was 31.2% (<jats:italic>n<\/jats:italic>\u2009=\u2009139). Ninety-three patients received isoniazid, 15.1% had some adverse reactions, but only 4 (4.3%) had to discontinue treatment. Two patients with latent tuberculosis under treatment with Isoniazid reactivated tuberculosis infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence in our study was within the range of other similar Mexican populations. Isoniazid treatment had an adequate tolerance and adherence. Longer follow-up could offer more information on the risk of reactivation in both groups.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06236-y","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:19:37Z","timestamp":1622495977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City"],"prefix":"10.1186","volume":"21","author":[{"given":"Erick Antonio","family":"Osorio-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Vilar-Compte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaquelyn","family":"Garc\u00eda-Tirado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Martin-Onraet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"issue":"1","key":"6236_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1.","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"6236_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.molmed.2007.03.004","volume":"13","author":"P Andersen","year":"2007","unstructured":"Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med. 2007;13(5):175\u201382. https:\/\/doi.org\/10.1016\/j.molmed.2007.03.004.","journal-title":"Trends Mol Med"},{"issue":"1","key":"6236_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1590\/S0036-36342010000100011","volume":"52","author":"JA Barrios-Pay\u00e1n","year":"2010","unstructured":"Barrios-Pay\u00e1n JA, Casta\u00f1\u00f3n-Arreola M, Flores-Valdez MA, Hern\u00e1ndez-Pando R. Aspectos biol\u00f3gicos, cl\u00ednicos y epidemiol\u00f3gicos de la tuberculosis latente. Salud Publica Mex. 2010;52(1):70\u20138. https:\/\/doi.org\/10.1590\/S0036-36342010000100011.","journal-title":"Salud Publica Mex"},{"key":"6236_CR4","volume-title":"Global Tuberculosis Report 2019","author":"WHO","year":"2019","unstructured":"WHO. Global Tuberculosis Report 2019. Geneva: World Health Organization; 2019."},{"issue":"10","key":"6236_CR5","first-page":"879","volume":"79","author":"FR Hauck","year":"2009","unstructured":"Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician. 2009;79(10):879\u201386.","journal-title":"Am Fam Physician"},{"issue":"9","key":"6236_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jama.2016.10357","volume":"316","author":"LC Kahwati","year":"2016","unstructured":"Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, et al. Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;316(9):970\u201383. https:\/\/doi.org\/10.1001\/jama.2016.10357.","journal-title":"JAMA"},{"issue":"9","key":"6236_CR7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2016.11046","volume":"316","author":"US Preventive Services Task Force","year":"2016","unstructured":"Preventive Services Task Force US, Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman L, Davidson KW, et al. Screening for latent tuberculosis infection in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(9):962\u20139. https:\/\/doi.org\/10.1001\/jama.2016.11046.","journal-title":"JAMA"},{"issue":"1","key":"6236_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1164\/ajrccm.153.1.8542139","volume":"153","author":"AL Kritski","year":"1996","unstructured":"Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153(1):331\u20135. https:\/\/doi.org\/10.1164\/ajrccm.153.1.8542139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"6236_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3122\/jabfm.2014.05.140062","volume":"27","author":"HJ Chapman","year":"2014","unstructured":"Chapman HJ, Lauzardo M. Advances in diagnosis and treatment of latent tuberculosis infection. J Am Board Fam Med. 2014;27(5):704\u201312. https:\/\/doi.org\/10.3122\/jabfm.2014.05.140062.","journal-title":"J Am Board Fam Med"},{"issue":"1","key":"6236_CR10","doi-asserted-by":"publisher","first-page":"e2014026","DOI":"10.4084\/mjhid.2014.026","volume":"6","author":"L Anibarro","year":"2014","unstructured":"Anibarro L, Pena A. Tuberculosis in patients with Haematological malignancies. Mediterr J Hematol Infect Dis. 2014;6(1):e2014026. https:\/\/doi.org\/10.4084\/mjhid.2014.026.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"5","key":"6236_CR11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s15010-013-0489-9","volume":"41","author":"EM S\u00e1nchez-Garc\u00eda","year":"2013","unstructured":"S\u00e1nchez-Garc\u00eda EM, Gamallo R, Blanco-Moure A, Viejo MA, Amador L, Anibarro L. Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies. Infection. 2013;41(5):903\u20137. https:\/\/doi.org\/10.1007\/s15010-013-0489-9.","journal-title":"Infection"},{"issue":"1","key":"6236_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1378\/chest.08-2575","volume":"136","author":"L Richeldi","year":"2009","unstructured":"Richeldi L, Losi M, D\u2019Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest. 2009;136(1):198\u2013204. https:\/\/doi.org\/10.1378\/chest.08-2575.","journal-title":"Chest"},{"issue":"supplement_3","key":"6236_CR13","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","volume":"161","author":"Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection: This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999","year":"2000","unstructured":"Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection: This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am J Respir Crit Care Med. 2000;161(supplement_3):S221\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"6236_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.bbmt.2020.03.013","volume":"26","author":"C Bourlon","year":"2020","unstructured":"Bourlon C, Camacho-Hern\u00e1ndez R, Fierro-Angulo OM, Acosta-Medina AA, Bourlon MT, Niembro-Ortega MD, et al. Latent tuberculosis in hematopoietic stem cell transplantation: diagnostic and therapeutic strategies to Prevent disease activation in an endemic population. Biol Blood Marrow Transpl. 2020;26(7):1350\u20134. https:\/\/doi.org\/10.1016\/j.bbmt.2020.03.013.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"6236_CR15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1086\/503917","volume":"42","author":"M Kamboj","year":"2006","unstructured":"Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with Cancer. Clin Infect Dis. 2006;42(11):1592\u20135. https:\/\/doi.org\/10.1086\/503917.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"6236_CR16","first-page":"555","volume":"60","author":"International Union Against Tuberculosis Committee on Prophylaxis","year":"1982","unstructured":"International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ. 1982;60(4):555\u201364.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"6236_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1471-2334-12-169","volume":"12","author":"JM Ramos","year":"2012","unstructured":"Ramos JM, Robledano C, Masi\u00e1 M, Belda S, Padilla S, Rodr\u00edguez JC, et al. Contribution of Interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: A comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis. 2012;12(1):169.","journal-title":"BMC Infect Dis"},{"issue":"8","key":"6236_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMra1200894","volume":"368","author":"A Zumla","year":"2013","unstructured":"Zumla A, Raviglione M, Hafner R, Fordham von Reyn C. Tuberculosis. N Engl J Med. 2013;368(8):745\u201355. https:\/\/doi.org\/10.1056\/NEJMra1200894.","journal-title":"N Engl J Med"},{"issue":"1","key":"6236_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1186\/s12879-016-1959-3","volume":"16","author":"E Oren","year":"2016","unstructured":"Oren E, Fiero MH, Barrett E, Anderson B, Nu\u1fc6ez M, Gonzalez-Salazar F. Detection of latent tuberculosis infection among migrant farmworkers along the US-Mexico border. BMC Infect Dis. 2016;16(1):630. https:\/\/doi.org\/10.1186\/s12879-016-1959-3.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"6236_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.arcmed.2015.03.009","volume":"46","author":"G Mart\u00ednez-Aguilar","year":"2015","unstructured":"Mart\u00ednez-Aguilar G, Serrano CJ, Casta\u00f1eda-Delgado JE, Mac\u00edas-Segura N, Hern\u00e1ndez-Delgadillo N, Enciso-Moreno L, et al. Associated risk factors for latent tuberculosis infection in subjects with diabetes. Arch Med Res. 2015;46(3):221\u20137. https:\/\/doi.org\/10.1016\/j.arcmed.2015.03.009.","journal-title":"Arch Med Res"},{"issue":"9","key":"6236_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00296-015-3246-9","volume":"35","author":"L P\u00e9rez-Barbosa","year":"2015","unstructured":"P\u00e9rez-Barbosa L, Esquivel-Valerio JA, Arana-Guajardo AC, Vega-Morales D, Riega-Torres J, Garza-Elizondo MA. Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients. Rheumatol Int. 2015;35(9):1555\u20139. https:\/\/doi.org\/10.1007\/s00296-015-3246-9.","journal-title":"Rheumatol Int"},{"issue":"10","key":"6236_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","volume":"149","author":"D Menzies","year":"2008","unstructured":"Menzies D, Long R, Trajman A, Dion M-J, Yang J, Al Jahdali H, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689\u201397. https:\/\/doi.org\/10.7326\/0003-4819-149-10-200811180-00003.","journal-title":"Ann Intern Med"},{"issue":"11","key":"6236_CR23","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/cid\/ciw132","volume":"62","author":"MJ Garcia","year":"2016","unstructured":"Garcia MJ, Lopez MR. Editorial Commentary : do we have strategies to improve the Preventive treatment of latent tuberculosis infection? Clin Infect Dis. 2016;62(11):1401\u20132. https:\/\/doi.org\/10.1093\/cid\/ciw132.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"6236_CR24","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/cid\/ciw126","volume":"62","author":"RN Moro","year":"2016","unstructured":"Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, et al. Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada. Clin Infect Dis. 2016;62(11):1390\u2013400. https:\/\/doi.org\/10.1093\/cid\/ciw126.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6236_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1086\/427802","volume":"40","author":"J Ena","year":"2005","unstructured":"Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40(5):670\u20136. https:\/\/doi.org\/10.1086\/427802.","journal-title":"Clin Infect Dis"},{"issue":"50","key":"6236_CR26","first-page":"1029","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","unstructured":"Centers for Disease Control and Prevention (CDC). Notes from the field: national shortage of isoniazid 300 mg tablets. MMWR Morb Mortal Wkly Rep. 2012;61(50):1029.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"6236_CR27","doi-asserted-by":"publisher","first-page":"e22500","DOI":"10.1371\/journal.pone.0022500","volume":"6","author":"M Pothukuchi","year":"2011","unstructured":"Pothukuchi M, Nagaraja SB, Kelamane S, Satyanarayana S, Babu S, et al. Tuberculosis contact screening and Isoniazid preventive therapy in a South Indian district: operational issues for programmatic consideration. PLoS ONE. 2011;6(7):e22500 Marais BJ, editor.","journal-title":"PLoS ONE"},{"issue":"20","key":"6236_CR28","first-page":"398","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","unstructured":"Centers for Disease Control and Prevention (CDC). Impact of a shortage of first-line antituberculosis medication on tuberculosis control - United States, 2012\u20132013. MMWR Morb Mortal Wkly Rep. 2013;62(20):398\u2013400.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"6236_CR29","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S1473-3099(16)30139-6","volume":"17","author":"F Olea-Popelka","year":"2017","unstructured":"Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, et al. Zoonotic tuberculosis in human beings caused by Mycobacterium bovis \u2014a call for action. Lancet Infect Dis. 2017;17(1):e21\u20135. https:\/\/doi.org\/10.1016\/S1473-3099(16)30139-6.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"6236_CR30","doi-asserted-by":"publisher","first-page":"e2177","DOI":"10.1371\/journal.pntd.0002177","volume":"7","author":"P Torres-Gonzalez","year":"2013","unstructured":"Torres-Gonzalez P, Soberanis-Ramos O, Martinez-Gamboa A, Chavez-Mazari B, Barrios-Herrera MT, Torres-Rojas M, et al. Prevalence of latent and active tuberculosis among dairy farm workers exposed to cattle infected by Mycobacterium bovis. PLoS Negl Trop Dis. 2013;7(4):e2177. https:\/\/doi.org\/10.1371\/journal.pntd.0002177.","journal-title":"PLoS Negl Trop Dis"},{"issue":"9","key":"6236_CR31","doi-asserted-by":"publisher","first-page":"e0004124","DOI":"10.1371\/journal.pntd.0004124","volume":"9","author":"M Bobadilla-del Valle","year":"2015","unstructured":"Bobadilla-del Valle M, Torres-Gonz\u00e1lez P, Cervera-Hern\u00e1ndez ME, Mart\u00ednez-Gamboa A, Crabtree-Ramirez B, Ch\u00e1vez-Mazari B, et al. Trends of Mycobacterium Bovis isolation and first-line anti-tuberculosis drug susceptibility profile: a fifteen-year laboratory-based surveillance. PLoS Negl Trop Dis. 2015;9(9):e0004124.","journal-title":"PLoS Negl Trop Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06236-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T21:19:50Z","timestamp":1622495990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6236"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06236-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Committee \u201c<i>Comit\u00e9 de \u00c9tica en Investigaci\u00f3n\u201d<\/i> (number Rev.\/0014\/19) of the INCan. Due to the nature of the study, being observational and retrospective, the INCan\u2019s \u201c<i>Comit\u00e9 de \u00c9tica en Investigaci\u00f3n<\/i>\u201d waived the written informed consent. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"510"}}